ACPU
CLVS

Arrowgrass Capital Partners (US)’s Clovis Oncology, Inc. CLVS Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-174,569
Closed -$16.3M – 630
2017
Q2 		$16.3M Buy
+174,569
New +$10.7M 0.12% 216
2016
Q2 		– Sell
-50,000
Closed -$960K – 456
2016
Q1 		$960K Buy
+50,000
New +$1.06M 0.01% 320
2015
Q3 		– Sell
-22,500
Closed -$1.98M – 543
2015
Q2 		$1.98M Buy
+22,500
New +$1.93M 0.03% 336
2015
Q1 		– Sell
-15,000
Closed -$840K – 546
2014
Q4 		$840K Sell
15,000
-5,000
-25% -$263K 0.01% 317
2014
Q3 		$907K Buy
+20,000
New +$835K 0.02% 240

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return